PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

U.S. Drug Discovery Contract Research Organization Markets - New analysis from Frost & Sullivan, U.S. Drug Discovery Contract Research Organization Markets, reveals that the market earned revenues of $7.44 billion in 2006 and is likely to reach $19.35 billion in 2013.
U.S. Drug Discovery Contract Research Organization Markets

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2006/11/21 - New analysis from Frost & Sullivan, U.S. Drug Discovery Contract Research Organization Markets, reveals that the market earned revenues of $7.44 billion in 2006 and is likely to reach $19.35 billion in 2013..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The contract research organization (CRO) market presents a mix of numerous challenges and opportunities and is likely to provide pharmaceutical and biotechnology market participants the opportunity to achieve their strategic objectives by offering services that seek to reduce cost and time-to-market drug candidates. CROs are likely to capitalize on this tremendous opportunity by pursuing a mix of organic and inorganic growth initiatives that will ensure greater penetration of the market and higher share of R&D spending.

New analysis from Frost & Sullivan, U.S. Drug Discovery Contract Research Organization Markets, reveals that the market earned revenues of $7.44 billion in 2006 and is likely to reach $19.35 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Drug Discovery Contract Research Organization Markets, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

Biotechnology and pharmaceutical companies are outsourcing their R&D to CROs due to the lack of internal expertise, infrastructure, mounting costs of drug development, and stringent regulatory guidelines. Biotechnology companies have limited investments in development infrastructure compared to their pharmaceutical counterparts. This is resulting in greater business volumes for CROs from the biotechnology market.

“The increase in globalization of trials is likely to result in several CROs expanding across geographical boundaries and augmenting their capacity to cater to this opportunity,” notes Frost & Sullivan Research Analyst Barath Shankar S. “As the market continues to enlarge and inorganic growth emerges as a critical component of this expansion, the trend of deepening focus on core expertise is becoming crucial.”

Along with offering required expertise to manage complex global trials across a variety of therapeutic segments, CROs provide a full line of preclinical and clinical services, which aid rapid expansion of the drug discovery CRO market. Their ability to deliver clinical trial participants with high levels of efficiency and productivity are further strengthening the need for companies to outsource R&D.

Several leading CROs have proactively established global presence through a strategic mix of organic and inorganic growth strategies. Achieving the right breadth and depth of services can prominently position these CROs in the highly competitive and rapidly growing market.

Market participants can gain prominence by shifting from the traditional route of drug discovery to the emerging "proof of concept" model. The complexity of the drug discovery process necessitates high degree of technical change to drive innovation and achieve greater efficiency in commercially launching products.

“However, there is an increasing level of commoditization of CRO services due to similarity in quality and range of services provided,” observes Shankar. “CROs can benefit from offering cost-effective services to retain companies likely to change loyalties based on lower cost benefit.”

The U.S. Drug Discovery Contract Research Organization Markets is part of the Pharmaceuticals and Biotechnology subscription, which also includes research in the following markets: global pharmaceutical contract manufacturing, analysis of top 10 specialty pharmaceutical companies, and global vaccines. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Analyst interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


U.S. Drug Discovery Contract Research Organization Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Deb Sheppard - Medium Psychic Author Speaker

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)